Equity Research firms currently have a positive stance on shares of TG Therapeutics, Inc. (NASDAQ:TGTX). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.40. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $24.00 on a short term basis.
At the time of writing, the stock was trading at $8.69. This represents a change from the opening price of 2.60%. In terms of performance, year to date, the stock is -29.42%. The monthly stock performance comes in at 23.46%. For the quarter, shares are performing at 36.69%. Weekly performance analysis shows the equity at 12.72%.
In taking a look at technical levels, shares are trading 29.38% away from the 50 day simple moving average and 9.91% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -41.56% away from it’s 52- week high and 60.63% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, TG Therapeutics, Inc.’s RSI stands at 75.61. In looking at volatility levels, the shares saw weekly volatility of 5.93% and 5.46% over the past month.